JP2015508652A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015508652A5 JP2015508652A5 JP2014557602A JP2014557602A JP2015508652A5 JP 2015508652 A5 JP2015508652 A5 JP 2015508652A5 JP 2014557602 A JP2014557602 A JP 2014557602A JP 2014557602 A JP2014557602 A JP 2014557602A JP 2015508652 A5 JP2015508652 A5 JP 2015508652A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- binding
- binding polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000009739 binding Methods 0.000 claims 53
- 229920001184 polypeptide Polymers 0.000 claims 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims 36
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 102100027287 Serpin H1 Human genes 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 101000836383 Homo sapiens Serpin H1 Proteins 0.000 claims 8
- 108010038679 colligin Proteins 0.000 claims 6
- 102000009027 Albumins Human genes 0.000 claims 3
- 108010088751 Albumins Proteins 0.000 claims 3
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 claims 2
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 claims 2
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000178 monomer Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1250145-8 | 2012-02-20 | ||
| SE1250145 | 2012-02-20 | ||
| PCT/SE2013/050139 WO2013126006A1 (en) | 2012-02-20 | 2013-02-19 | Polypeptides binding to human complement c5 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201509A Division JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015508652A JP2015508652A (ja) | 2015-03-23 |
| JP2015508652A5 true JP2015508652A5 (enExample) | 2016-04-07 |
| JP6276202B2 JP6276202B2 (ja) | 2018-02-07 |
Family
ID=49006055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014557602A Active JP6276202B2 (ja) | 2012-02-20 | 2013-02-19 | ヒト補体ｃ５に結合するポリペプチド |
| JP2017201509A Active JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017201509A Active JP6719438B2 (ja) | 2012-02-20 | 2017-10-18 | ヒト補体ｃ５に結合するポリペプチド |
Country Status (31)
| Country | Link |
|---|---|
| US (5) | US9808502B2 (enExample) |
| EP (3) | EP4616914A3 (enExample) |
| JP (2) | JP6276202B2 (enExample) |
| KR (2) | KR102149028B1 (enExample) |
| CN (1) | CN104114574B (enExample) |
| AU (3) | AU2013222836B2 (enExample) |
| BR (1) | BR112014020427B1 (enExample) |
| CA (1) | CA2863862C (enExample) |
| CY (1) | CY1121455T1 (enExample) |
| DK (1) | DK2817329T3 (enExample) |
| ES (1) | ES2715638T3 (enExample) |
| HR (1) | HRP20190522T1 (enExample) |
| HU (1) | HUE041996T2 (enExample) |
| IL (2) | IL234114B (enExample) |
| LT (1) | LT2817329T (enExample) |
| ME (1) | ME03640B (enExample) |
| MX (1) | MX359201B (enExample) |
| MY (1) | MY167232A (enExample) |
| NZ (1) | NZ628625A (enExample) |
| PH (1) | PH12014501604B1 (enExample) |
| PL (1) | PL2817329T3 (enExample) |
| PT (1) | PT2817329T (enExample) |
| RS (1) | RS58503B1 (enExample) |
| RU (1) | RU2654668C2 (enExample) |
| SG (1) | SG11201404942UA (enExample) |
| SI (1) | SI2817329T1 (enExample) |
| SM (1) | SMT201900189T1 (enExample) |
| TR (1) | TR201903840T4 (enExample) |
| UA (1) | UA117096C2 (enExample) |
| WO (1) | WO2013126006A1 (enExample) |
| ZA (1) | ZA201406773B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| JP6396303B2 (ja) | 2012-10-25 | 2018-09-26 | アフィボディ・アーベー | アルブミン結合を含有するタンパク質の分離方法 |
| PL2912054T3 (pl) * | 2012-10-25 | 2017-11-30 | Affibody Ab | Polipeptyd wiążący albuminę |
| WO2015028558A1 (en) | 2013-08-28 | 2015-03-05 | Swedish Orphan Biovitrum Ab (Publ) | Stable polypeptides binding to human complement c5 |
| US9982022B2 (en) | 2013-08-28 | 2018-05-29 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| BR122021025449B1 (pt) * | 2014-06-12 | 2024-02-15 | Ra Pharmaceuticals, Inc | Composto, polipeptídeo e composição compreendendo o mesmo |
| WO2015189431A1 (en) * | 2014-06-13 | 2015-12-17 | Affibody Ab | New polypeptide |
| WO2015189430A1 (en) * | 2014-06-13 | 2015-12-17 | Affibody Ab | New polypeptide |
| DE102014225439A1 (de) * | 2014-12-10 | 2016-06-16 | Zf Friedrichshafen Ag | Stufenplanet |
| KR20240110106A (ko) * | 2015-01-12 | 2024-07-12 | 애피바디 에이비 | Il-17a-결합 폴리펩티드 |
| SMT202100688T1 (it) | 2015-01-28 | 2022-01-10 | Ra Pharmaceuticals Inc | Modulatori di attività del complemento |
| KR20260070290A (ko) | 2015-12-16 | 2026-05-18 | 유씨비 홀딩스 인코포레이티드 | 보체 활성의 조절인자 |
| JP7301741B2 (ja) | 2016-12-07 | 2023-07-03 | ラ ファーマシューティカルズ インコーポレイテッド | 補体活性のモジュレータ |
| UY37651A (es) * | 2017-03-31 | 2018-10-31 | Swedish Orphan Biovitrum Ab Publ | Polipéptido de unión al il-1r-i |
| IL307197B2 (en) * | 2017-07-11 | 2026-03-01 | Alexion Pharma Inc | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
| PH12021552525A1 (en) | 2019-04-03 | 2022-08-08 | Clean Earth Tech Pty Ltd | Materials and processes for recovering precious metals |
| ES2973767T3 (es) | 2019-06-04 | 2024-06-24 | Ra Pharmaceuticals Inc | Tratamiento de enfermedades inflamatorias con inhibidores del complemento |
| WO2021089695A1 (en) * | 2019-11-05 | 2021-05-14 | Affibody Ab | Polypeptides |
| CN116472065A (zh) * | 2020-10-05 | 2023-07-21 | 阿雷克森制药公司 | 治疗皮肌炎的方法 |
| WO2024227886A1 (en) | 2023-05-02 | 2024-11-07 | Mebrahtu Aman | Bispecific binding molecule |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5135916A (en) | 1989-06-12 | 1992-08-04 | Oklahoma Medical Research Foundation | Inhibition of complement mediated inflammatory response |
| SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
| US6267964B1 (en) | 1989-08-01 | 2001-07-31 | Affibody Technology Sweden Ab | Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives |
| US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| US5627264A (en) | 1994-03-03 | 1997-05-06 | Alexion Pharmaceuticals, Inc. | Chimeric complement inhibitor proteins |
| CA2184356A1 (en) | 1994-03-03 | 1995-09-08 | Russell P. Rother | Terminal complement inhibitor fusion genes and proteins |
| AU2191795A (en) | 1994-03-23 | 1995-10-09 | Alexion Pharmaceuticals, Inc. | Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation |
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| AU3729295A (en) | 1994-09-23 | 1996-04-09 | Alexion Pharmaceuticals, Inc. | Methods for the treatment of inflammatory joint disease |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| ATE449791T1 (de) | 2000-10-10 | 2009-12-15 | Genentech Inc | Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| MXPA04001301A (es) * | 2001-08-17 | 2004-07-08 | Tanox Inc | Inhibidores de la ruta del complemento que se unen a c5 y c5a son evitar la formacion de c5b. |
| US20040142325A1 (en) * | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| ITMI20021527A1 (it) | 2002-07-11 | 2004-01-12 | Consiglio Nazionale Ricerche | Anticorpi anti componente c5 del complemento e loro uso |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| MXPA05005909A (es) | 2002-12-02 | 2005-08-26 | Resistentia Pharmaceuticals Ab | Metodos y materiales para el tratamiento de condiciones inflamatorias usando un polipeptido que contiene un segmento aminoacido propio cs y un segmento aminoacido no propio. |
| US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| US7884188B2 (en) | 2003-06-02 | 2011-02-08 | Varleigh Immuno Pharmaceuticals (Vip) Ltd | Complement inhibitors |
| CA2579635A1 (en) * | 2003-09-10 | 2005-03-17 | Baxter International Inc. | Peptides that inhibit complement activation |
| SE0400274D0 (sv) | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| WO2005090381A1 (en) | 2004-03-24 | 2005-09-29 | Auckland Uniservices Limited | Set1 proteins and uses therefor |
| US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
| GB0518443D0 (en) * | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| DK2500030T4 (en) * | 2005-11-04 | 2018-10-29 | Genentech Inc | Use of complement pathway inhibitors for the treatment of eye diseases |
| GB0524788D0 (en) | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
| DK1991275T3 (en) | 2006-03-08 | 2014-12-08 | Archemix Llc | Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES |
| HUE066795T2 (hu) | 2006-03-15 | 2024-09-28 | Alexion Pharma Inc | Paroxysmalis nocturnalis haemoglobinuriában szenvedõ betegek kezelése egy komplement inhibitorral |
| WO2008010902A2 (en) | 2006-07-06 | 2008-01-24 | The Trustees Of The University Of Pennsylvania | Regulation of tlr signaling by complement |
| WO2008030505A2 (en) | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| GB0617734D0 (en) | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| AR062709A1 (es) * | 2006-09-08 | 2008-11-26 | Genentech Inc | Antagonistas del gen wnt y su uso en el diagnostico y tratamiento de trastornos mediados por el wnt |
| WO2008113834A2 (en) * | 2007-03-22 | 2008-09-25 | Novartis Ag | C5 antigens and uses thereof |
| CN101932337A (zh) | 2007-06-11 | 2010-12-29 | 宾夕法尼亚大学董事会 | 替代途径的血清灭菌蛋白调节及其应用 |
| DE08786222T1 (de) | 2007-07-31 | 2010-11-25 | Affibody Ab | Neue albuminbindende zusammensetzungen, verfahren und anwendungen |
| US8852869B2 (en) | 2007-09-05 | 2014-10-07 | Immunobond Aps | Method of determining functional deficiencies in the complement system |
| EP2077272A1 (en) | 2007-12-21 | 2009-07-08 | Affibody AB | Polypeptide libraries with a predetermined scaffold |
| US9187535B2 (en) * | 2007-12-19 | 2015-11-17 | Affibody Ab | Polypeptide derived from protein A and able to bind PDGF |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| EP2072525A1 (en) | 2007-12-21 | 2009-06-24 | Affibody AB | New polypeptides having affinity for HER2 |
| PY09026846A (es) * | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| JP6223659B2 (ja) | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| EP2327725A1 (en) * | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
| WO2011109338A1 (en) | 2010-03-01 | 2011-09-09 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating degos' disease |
| US20110245469A1 (en) * | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives |
| AU2011245117B2 (en) | 2010-04-30 | 2015-03-12 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies and methods for using the antibodies |
| BR112013000452A2 (pt) | 2010-07-09 | 2020-02-11 | Affibody Ab | Polipeptídeo de ligação de albumina, proteína de fusão ou conjugado, polinucleotídeo, método para produzir um polipeptídeo, composição, método para a preparação de uma composição, e, método para aumentar a solubilidade de um composto |
| JP6293659B2 (ja) | 2011-07-01 | 2018-03-14 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 抗プロペルジン抗体およびその使用 |
| KR102149028B1 (ko) | 2012-02-20 | 2020-08-27 | 스위디쉬 오르펀 바이오비트럼 에이비 (피유비엘) | 인간 보체 c5에 결합하는 폴리펩티드 |
| US9238676B2 (en) | 2012-05-17 | 2016-01-19 | Ra Pharmaceuticals, Inc. | Peptide and peptidomimetic inhibitors |
| JP5980104B2 (ja) | 2012-11-22 | 2016-08-31 | 三菱電機株式会社 | 液晶表示装置の製造方法および液晶表示装置の製造システム |
| JP6577868B2 (ja) | 2012-12-19 | 2019-09-18 | アフィボディ・アーベー | 新規ポリペプチド |
| MX366425B (es) | 2013-03-15 | 2019-07-04 | Affibody Ab | Nuevos polipeptidos. |
| US9982022B2 (en) | 2013-08-28 | 2018-05-29 | Affibody Ab | Binding polypeptides having a mutated scaffold |
| WO2015028558A1 (en) | 2013-08-28 | 2015-03-05 | Swedish Orphan Biovitrum Ab (Publ) | Stable polypeptides binding to human complement c5 |
| NZ711451A (en) | 2014-03-07 | 2016-05-27 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
-
2013
- 2013-02-19 KR KR1020147025537A patent/KR102149028B1/ko active Active
- 2013-02-19 KR KR1020207024244A patent/KR102336895B1/ko active Active
- 2013-02-19 TR TR2019/03840T patent/TR201903840T4/tr unknown
- 2013-02-19 NZ NZ628625A patent/NZ628625A/en unknown
- 2013-02-19 EP EP25168811.5A patent/EP4616914A3/en active Pending
- 2013-02-19 DK DK13752233.0T patent/DK2817329T3/en active
- 2013-02-19 PT PT13752233T patent/PT2817329T/pt unknown
- 2013-02-19 HU HUE13752233A patent/HUE041996T2/hu unknown
- 2013-02-19 AU AU2013222836A patent/AU2013222836B2/en active Active
- 2013-02-19 BR BR112014020427-6A patent/BR112014020427B1/pt active IP Right Grant
- 2013-02-19 SI SI201331358T patent/SI2817329T1/sl unknown
- 2013-02-19 CN CN201380009789.0A patent/CN104114574B/zh active Active
- 2013-02-19 SG SG11201404942UA patent/SG11201404942UA/en unknown
- 2013-02-19 EP EP13752233.0A patent/EP2817329B1/en active Active
- 2013-02-19 MY MYPI2014702257A patent/MY167232A/en unknown
- 2013-02-19 RS RS20190369A patent/RS58503B1/sr unknown
- 2013-02-19 JP JP2014557602A patent/JP6276202B2/ja active Active
- 2013-02-19 WO PCT/SE2013/050139 patent/WO2013126006A1/en not_active Ceased
- 2013-02-19 ES ES13752233T patent/ES2715638T3/es active Active
- 2013-02-19 EP EP18213025.2A patent/EP3511339B1/en active Active
- 2013-02-19 ME MEP-2019-84A patent/ME03640B/me unknown
- 2013-02-19 HR HRP20190522TT patent/HRP20190522T1/hr unknown
- 2013-02-19 SM SM20190189T patent/SMT201900189T1/it unknown
- 2013-02-19 RU RU2014137303A patent/RU2654668C2/ru active
- 2013-02-19 US US14/378,522 patent/US9808502B2/en active Active
- 2013-02-19 CA CA2863862A patent/CA2863862C/en active Active
- 2013-02-19 LT LTEP13752233.0T patent/LT2817329T/lt unknown
- 2013-02-19 MX MX2014009879A patent/MX359201B/es active IP Right Grant
- 2013-02-19 UA UAA201409807A patent/UA117096C2/uk unknown
- 2013-02-19 PL PL13752233T patent/PL2817329T3/pl unknown
-
2014
- 2014-07-11 PH PH12014501604A patent/PH12014501604B1/en unknown
- 2014-08-13 IL IL234114A patent/IL234114B/en active IP Right Grant
- 2014-09-16 ZA ZA2014/06773A patent/ZA201406773B/en unknown
-
2017
- 2017-09-29 US US15/721,507 patent/US10206975B2/en active Active
- 2017-10-12 AU AU2017245376A patent/AU2017245376B2/en active Active
- 2017-10-18 JP JP2017201509A patent/JP6719438B2/ja active Active
-
2018
- 2018-12-20 US US16/228,181 patent/US11123401B2/en active Active
-
2019
- 2019-03-20 CY CY20191100331T patent/CY1121455T1/el unknown
- 2019-06-30 IL IL267724A patent/IL267724B/en unknown
- 2019-10-18 AU AU2019250239A patent/AU2019250239B2/en active Active
-
2021
- 2021-09-20 US US17/479,101 patent/US12083160B2/en active Active
-
2024
- 2024-09-09 US US18/828,700 patent/US20250332214A1/en active Pending